179 related articles for article (PubMed ID: 15790413)
1. Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696].
Ostadal P; Alan D; Hajek P; Vejvoda J; Mates M; Blasko P; Veselka J; Kvapil M; Kettner J; Wiendl M; Aschermann O; Slaby J; Nemecek E; Holm F; Rac M; Macek M; Cepova J
Curr Control Trials Cardiovasc Med; 2005 Mar; 6(1):4. PubMed ID: 15790413
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial).
Ostadal P; Alan D; Vejvoda J; Kukacka J; Macek M; Hajek P; Mates M; Kvapil M; Kettner J; Wiendl M; Aschermann O; Slaby J; Holm F; Telekes P; Horak D; Blasko P; Zemanek D; Veselka J; Cepova J
Trials; 2010 May; 11():61. PubMed ID: 20500832
[TBL] [Abstract][Full Text] [Related]
3. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale.
Dominguez-Rodriguez A; Fard SS; Abreu-Gonzalez P; Bosa-Ojeda F; Consuegra-Sanchez L; Jiménez-Sosa A; Grande AS; Kaski JC
Cardiovasc Drugs Ther; 2009 Jun; 23(3):243-7. PubMed ID: 19229603
[TBL] [Abstract][Full Text] [Related]
4. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
[TBL] [Abstract][Full Text] [Related]
5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
6. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM
Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797
[TBL] [Abstract][Full Text] [Related]
7. The case for intensive statin therapy after acute coronary syndromes.
Schwartz GG; Olsson AG
Am J Cardiol; 2005 Sep; 96(5A):45F-53F. PubMed ID: 16126023
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
9. Statins for acute coronary syndrome.
Vale N; Nordmann AJ; Schwartz GG; de Lemos J; Colivicchi F; den Hartog F; Ostadal P; Macin SM; Liem AH; Mills E; Bhatnagar N; Bucher HC; Briel M
Cochrane Database Syst Rev; 2011 Jun; (6):CD006870. PubMed ID: 21678362
[TBL] [Abstract][Full Text] [Related]
10. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
[TBL] [Abstract][Full Text] [Related]
11. [The effect of early fluvastatin therapy on inflammatory factors in acute coronary syndrome].
Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM; Peng J
Zhonghua Nei Ke Za Zhi; 2005 Mar; 44(3):184-7. PubMed ID: 15840256
[TBL] [Abstract][Full Text] [Related]
12. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Briel M; Schwartz GG; Thompson PL; de Lemos JA; Blazing MA; van Es GA; Kayikçioglu M; Arntz HR; den Hartog FR; Veeger NJ; Colivicchi F; Dupuis J; Okazaki S; Wright RS; Bucher HC; Nordmann AJ
JAMA; 2006 May; 295(17):2046-56. PubMed ID: 16670413
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
[TBL] [Abstract][Full Text] [Related]
14. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Albert MA; Staggers J; Chew P; Ridker PM;
Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
[TBL] [Abstract][Full Text] [Related]
15. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit.
Wright RS; Murphy JG; Bybee KA; Kopecky SL; LaBlanche JM
Mayo Clin Proc; 2002 Oct; 77(10):1085-92. PubMed ID: 12374252
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
Berwanger O; de Barros E Silva PGM; Dall Orto FTC; de Andrade PB; de Castro Bienert IR; Bosso CE; Mangione J; Polanczyk CA; Sousa A; Kalil R; de Moura Santos L; Sposito AC; Rech RL; Sousa ACS; Baldissera F; Nascimento BR; de Andrade Jesuíno I; Santucci EV; Damiani LP; Laranjeira LN; Borges de Oliveira JA; Giraldez RR; Cavalcanti AB; Pereira SB; Mattos LA; Armaganijan LV; Guimarães HP; Sousa JE; Alexander JH; Granger CB; Lopes RD
Am Heart J; 2018 Apr; 198():129-134. PubMed ID: 29653634
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: a Pilot Study.
Gao CZ; Ma QQ; Wu J; Liu R; Wang F; Bai J; Yang XJ; Fu Q; Wei P
Cell Physiol Biochem; 2018; 48(1):385-396. PubMed ID: 30016801
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
20. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome.
Schwartz GG; Fayyad R; Szarek M; DeMicco D; Olsson AG
Eur J Prev Cardiol; 2017 Aug; 24(12):1294-1296. PubMed ID: 28504565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
